GlassScriptPhysician profile
Sahar Ismail
NPI 1285991539
$7,838.08
in general payments reported to CMS, 2019-2025
22 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2021: $95.95 · 2022: $454 · 2023: $426 · 2024: $4,216 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608 · Travel and Lodging: $2,457 · Consulting Fee: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.54 |
| Travel and Lodging | $2,456.94 |
| Consulting Fee | $1,875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,124.34 | 2022-2025 | |
| Angiodynamics, INC. | $1,894.78 | 2024 | Angiovac |
| Abiomed | $1,159.26 | 2023-2025 | Impella |
| Medtronic, INC. | $995.98 | 2022-2024 | Onyx Frontier |
| Boston Scientific Corporation | $704.83 | 2019-2025 | Synergy, Avvigo Guidance System, Mamba |
| Abbott Laboratories | $267.85 | 2021-2025 | Optis |
| Medtronic Vascular, INC. | $142.32 | 2019 | |
| Inari Medical, INC. | $94.11 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $79.11 | 2021-2024 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.83 | 2022-2025 | Lifevest |
| Philips North America LLC | $54.27 | 2023-2025 | Extended Holter |
| Merck Sharp & Dohme LLC | $41.20 | 2024 | Verquvo |
| Heartflow, INC. | $38.08 | 2024 | |
| Kestra Medical Technology Services, INC. | $37.30 | 2024 | Assure Wcd |
| Reflow Medical INC | $29.63 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $18.50 | 2023 | Xarelto |
| Cordis US Corp. | $17.55 | 2024 | Infiniti |
| Chiesi USA, INC. | $16.55 | 2025 | Kengreal, Cleviprex |
| Amgen INC. | $13.46 | 2025 | Repatha |
| W. L. Gore & Associates, INC. | $13.33 | 2022 | |
| Cardinal Health 200 LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.